RAiD 10.26259/904420a2 Reliability of AI scoring for personalised melanoma immunotherapy
Dates
Start Date
End Date
Titles
Title
Title Type
Title Type:
Preferred full description or abstract.
Start Date
End Date
Language
Descriptions
Description
Description Type
Description Type:
Preferred full description or abstract
Language
Contributors
Contributor
Leader
Contact
Positions
Position
Position:
A Co-Investigator is a senior or key investigator involved in a research project who does not have the overall responsibility and authority of the Principal Investigator
Start Date
End Date
Roles
Conceptualization
Contributor
Leader
Contact
Positions
Position
Position:
A Co-Investigator is a senior or key investigator involved in a research project who does not have the overall responsibility and authority of the Principal Investigator
Start Date
End Date
Roles
Supervision
Organisations
Organisation ID
Roles
Role
Role:
The research organistion administratively responsible for the project; administering organisation
Start Date
End Date
RelatedObjects
No Entries
Alternate Identifier
No Entries
Alternate URLs
No Entries
Related RAiDs
No Entries
Access
Type
Type:
Open access refers to a resource that is immediately and permanently online, and free for all on the Web, without financial and technical barriers.The resource is either stored in the repository or referenced to an external journal or trustworthy archive.
Language
Text
Embargo Expiry
Subjects
Subject
Keywords
Text
Language
Raw Data
{ "metadata": { "created": 1723100673, "updated": 1742955860 }, "identifier": { "id": "https://raid.org/10.26259/904420a2", "schemaUri": "https://raid.org/", "registrationAgency": { "id": "https://ror.org/038sjwq14", "schemaUri": "https://ror.org/" }, "owner": { "id": "https://ror.org/02stey378", "schemaUri": "https://ror.org/", "servicePoint": 20000003 }, "raidAgencyUrl": "https://prod.static.raid.org.au/10.26259/904420a2", "license": "Creative Commons CC-0", "version": 2 }, "title": [ { "text": "Reliability of AI scoring for personalised melanoma immunotherapy", "type": { "id": "https://vocabulary.raid.org/title.type.schema/5", "schemaUri": "https://vocabulary.raid.org/title.type.schema/376" }, "startDate": "2023-01-31", "language": { "id": "eng", "schemaUri": "https://www.iso.org/standard/74575.html" } } ], "date": { "startDate": "2023-01-31", "endDate": "2025-02-28" }, "description": [ { "text": "Despite advances in cancer treatments and increased survival of advanced melanoma patients, most patients with advanced melanoma will still die when treated with routine immunotherapies due to immune evasive mechanisms[1]. The personalised immunotherapy program will, instead, ensure each patient’s cancer is screened for genetic and immune profiles to identify patients unlikely to benefit from standard therapies. These patients will then be assigned a novel clinical trial agent most likely to cure them based on the presence of the drug targets in the patient's tumour. It is anticipated that selecting treatments for patients, based on the presence of specific drug targets in the patient’s cancer, will improve cancer outcomes and increase the survival of people with cancer. \n\nThis project aims to optimise the multiplex immunohistochemistry staining panel that can be used to rapidly identify the profile of immune checkpoint targets in melanoma biopsies. Further, the project aims to elucidate the accuracy of the artificial intelligence (AI) program to correctly identity fluorescent threshold for immune marker positivity. \n\nThis project will accurately and cost effectively fast track patient assessment for immunotherapy treatments; thereby rapidly matching patients with effective therapies to increase the overall cure rate of advanced cancers.", "type": { "id": "https://vocabulary.raid.org/description.type.schema/318", "schemaUri": "https://vocabulary.raid.org/description.type.schema/320" }, "language": { "id": "eng", "schemaUri": "https://www.iso.org/standard/74575.html" } } ], "access": { "type": { "id": "https://vocabularies.coar-repositories.org/access_rights/c_abf2/", "schemaUri": "https://vocabularies.coar-repositories.org/access_rights/" }, "statement": { "text": "Access statement example text...", "language": { "id": "eng", "schemaUri": "https://www.iso.org/standard/74575.html" } }, "embargoExpiry": "2025-08-08" }, "alternateUrl": [], "contributor": [ { "id": "https://orcid.org/0000-0002-6270-1203", "schemaUri": "https://orcid.org/", "status": "UNAUTHENTICATED", "uuid": "c436daee-5f8f-4fef-ba27-305ad24718f5", "position": [ { "schemaUri": "https://vocabulary.raid.org/contributor.position.schema/305", "id": "https://vocabulary.raid.org/contributor.position.schema/308", "startDate": "2023-01-31" } ], "role": [ { "schemaUri": "https://credit.niso.org/", "id": "https://credit.niso.org/contributor-roles/conceptualization/" } ], "leader": true, "contact": true }, { "id": "https://orcid.org/0009-0006-7597-4813", "schemaUri": "https://orcid.org/", "status": "UNAUTHENTICATED", "uuid": "aa353b62-4e5d-4092-933b-7d0fbb13b93c", "position": [ { "schemaUri": "https://vocabulary.raid.org/contributor.position.schema/305", "id": "https://vocabulary.raid.org/contributor.position.schema/308", "startDate": "2023-01-31" } ], "role": [ { "schemaUri": "https://credit.niso.org/", "id": "https://credit.niso.org/contributor-roles/supervision/" } ], "leader": false, "contact": false } ], "organisation": [ { "id": "https://ror.org/02stey378", "schemaUri": "https://ror.org/", "role": [ { "schemaUri": "https://vocabulary.raid.org/organisation.role.schema/359", "id": "https://vocabulary.raid.org/organisation.role.schema/182", "startDate": "2023-01-31" } ] } ], "subject": [ { "id": "https://linked.data.gov.au/def/anzsrc-for/2020/3202", "schemaUri": "https://vocabs.ardc.edu.au/viewById/316", "keyword": [ { "text": "Subject keyword example text...", "language": { "id": "eng", "schemaUri": "https://www.iso.org/standard/74575.html" } } ] } ], "relatedRaid": [], "relatedObject": [], "alternateIdentifier": [], "spatialCoverage": [] }